Updates

Inspecs - Forecast EPS of 5.8p for full year, rising to 6.8p and 8.2p

October 2025

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

A frustrating performer for sure but not for long, I suspect. Broker Peel Hunt forecasts EPS of 5.8p this year, rising to 6.8p and 8.2p over the next two year but by looking at the muted share price reaction to Inspecs’ latest H1 results, you wouldn’t think it. CEO Richard Peck attributes some H1 softness to two temporary headwinds and investors haven’t been able to see beyond the noise. The first was tariff volatility linked to Trump-era policies, particularly an initial spike to 140% on Chinese imports into the US, which caused buyers to hold back on frame orders. The second was disruption at the US Department of Veterans Affairs, a major customer for Eschenbach’s low-vision magnifiers - a £30m segment - following staff cuts dri ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Alfa Financial Software - Untouchable versus rival products

Facilities by ADF - Utilisation spikes to 73% in Q3

Inspecs (December 2025)

Inspecs - Shares surge as 3 buyers line up (November 2025)

Inspecs (August 2025)

Inspecs - Key European rival goes into administration (May 2025)

Inspecs - Healthy signs for Inspecs (March 2025)

Inspecs (February 2025)

Inspecs - Large US business wins enhance H2 (October 2024)

Inspecs - Pretax profit guided to grow 22% to £9.9m (July 2024)

Inspecs - Q1 signals the corner is turned (May 2024)

Inspecs (February 2024)

Inspecs - Margins enhanced by moving Eschenbach acetate manufacture to Vietnam (January 2024)

Inspecs (October 2023)

Inspecs (August 2023)

Inspecs - EBITDA forecast to jump US$6m this year (July 2023)

Inspecs (May 2023)

Inspecs (February 2023)

Inspecs - Interesting new issue (March 2020)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X